Results 91 to 100 of about 23,433 (212)

Local Skin Inflammation in Cutaneous Leishmaniasis as a Source of Variable Pharmacokinetics and Therapeutic Efficacy of Liposomal Amphotericin B. [PDF]

, 2018
Disfiguring skin lesions caused by several species of the Leishmania parasite characterize cutaneous leishmaniasis (CL). Successful treatment of CL with intravenous (i.v.) liposomal amphotericin B (LAmB) relies on the presence of adequate antibiotic ...
Alavijeh, Mo, Croft, Simon L, Fortes Francisco, Amanda, Harris, Andy, Murdan, Sudaxshina, Van Bocxlaer, Katrien, Wijnant, Gert-Jan, Yardley, Vanessa   +7 more
core   +2 more sources

Treatment of Mucormycosis with Liposomal Amphotericin B, Posaconazole and Deferasirox : A Case Report

Journal of Microbiology and Infectious Diseases, 2016
In this paper, we present a 69 years old diabetic patient with mucormycosis who was succesfully treated with liposomal amphotericin B (LAMB), posaconazole and deferasirox despite having no adequate surgery.
Uğur Onal, Meltem Taşbakan, Tansu Yamazhan, Bilgin Arda, Husnu Pullukcu, Sercan Ulusoy, Oğuz Reşat Sipahi   +6 more
doaj   +1 more source

Candida auris, what do paediatricians need to know? [PDF]

, 2018
AW is supported by the Wellcome Trust Strategic Award (grant 097377) and the MRC Centre for Medical Mycology (grant MR/N006364/1) at the University of Aberdeen.Peer reviewedPublisher ...
Warris, Adilia
core   +1 more source

Comparison of the Activity of Free and Liposomal Amphotericin B In Vitro and in a Model of Systemic and Localized Murine Candidiasis [PDF]

, 2017
Because of the toxicity of amphotericin B-desoxycholate (AmB-d) during systemic therapy, less toxic forms of AmB, which promise to have a broader therapeutic index, are under investigation.
Pahls, Stephan, Schaffner, Andreas
core  

Single dose pharmacodynamics of amphotericin B against Aspergillus species in an in vitro pharmacokinetic/pharmacodynamic model [PDF]

, 2013
Conventional MIC testing of amphotericin B results in narrow MIC ranges challenging the detection of resistant strains. In order to discern amphotericin B pharmacodynamics, the in vitro activity of amphotericin B was studied against Aspergillus isolates ...
Al-Saigh, Rafal, Aristea, Velegraki, Meletiadis, Joseph, Siafakas, Nikolaos, Siopi, Maria, Zerva, Loukia   +5 more
core   +1 more source

Therapeutic and immunomodulatory activities of short-course treatment of murine visceral leishmaniasis with KALSOME™10, a new liposomal amphotericin B [PDF]

, 2015
Visceral leishmaniasis (VL), a potentially fatal disease, is most prevalent in the Indian subcontinent, East Africa and South America. Since the conventional antileishmanial drugs have many limitations we evaluated a new ergosterol rich liposomal ...
A Banerjee, A Banerjee, A Md, A Meyerhoff, AKS Chandel, Antara Banerjee, C Bogdan, F Afrin, F Lanternier, FC Szoka, G Gregoriadis, G Hernandez, GJ Timmers, H Goto, H Sachdeva, HW Ghalib, J Alvar, J Mishra, J Roychoudhury, JD Berman, JN Verma, K Pandey, M Larabi, Mohammad Asad, N Kumar, Nahid Ali, P Bhattacharya, PK Kushawaha, Pradyot Bhattacharya, PV Bodhe, R Kumar, RN Davidson, S Mondal, S Mondal, S Saha, S Saha, S Sundar, S Sundar, S Sundar, S Sundar, SA Ejazi, SL Croft, TJ Pucadyil   +42 more
core   +2 more sources

The direct costs of treating human visceral leishmaniasis in Brazil

Revista da Sociedade Brasileira de Medicina Tropical
INTRODUCTION: The drugs available for visceral leishmaniasis (VL) treatment in Brazil have specific characteristics in terms of operability, effectiveness, toxicity, and cost.
Tália Santana Machado de Assis, Dian Carlos Pinheiro Rosa, Eliane de Morais Teixeira, Gláucia Cota, André Luís Ferreira Azeredo-da-Silva, Guilherme Werneck, Ana Rabello   +6 more
doaj   +1 more source

Noncovalent complexation of amphotericin-B with Poly(α-glutamic acid).

, 2013
A noncovalent complex of amphotericin B (AmB) and poly(α-glutamic acid) (PGA) was prepared to develop a safe and stable formulation for the treatment of leishmaniasis. The loading of AmB in the complex was in the range of ∼20-50%.
Brocchini, Stephen, Croft, Simon L, Les, Karolina A, Mohamed-Ahmed, Abeer HA, Seifert, Karin   +4 more
core   +1 more source

Safety and efficacy of liposomal amphotericin B for the empirical therapy of invasive fungal infections in immunocompromised patients

Infection and Drug Resistance, 2012
Marisa H Miceli1, Pranatharthi Chandrasekar21Oakwood Hospital and Medical Center, Dearborn, 2Division of Infectious Diseases, Wayne State University School of Medicine, Detroit, MI, USAAbstract: Liposomal amphotericin B is a "true&quot ...
Miceli MH, Chandrasekar P
doaj  

Reworking the treatment of Indian Post kala-azar dermal leishmaniasis: A two-step therapy

Journal of Vector Borne Diseases
In the current scenario, treatment of Post kala-azar dermal leishmaniasis (PKDL) is intravenous liposomal amphotericin B or oral miltefosine. Over the years, there has been a gradual decline in the efficacy of miltefosine and a rise in permanent loss of ...
Sushruta Kathuria, Yugansh Gautam, Niti Khunger, Shruti Sharma, Ruchi Singh   +4 more
doaj   +1 more source